Connect with us

Technology

‘BOTCHED’ TV STAR DR. PAUL NASSIF AMONG TOP U.S. PLASTIC SURGEONS USING RENUVION® HELIUM PLASMA TECHNOLOGY IN COSMETIC PROCEDURES

Published

on

Doctors Attest to Advanced Energy Technology Device’s Transformative Solutions to Achieve Desired Results in Patients

CLEARWATER, Fla. , Sept. 13, 2022 /PRNewswire/ — Apyx Medical Corporation (NASDAQ: APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the release of a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology. 

Leading plastic surgeons across the country are sharing the transformative results they’ve achieved using Renuvion, a proprietary helium plasma and radiofrequency technology, on patients for cosmetic procedures in their practices.

In a video featuring celebrity plastic surgeon and co-host of the hit television series, ‘Botched’  Dr. Paul Nassif, New York City facial surgeon Dr. Tabasum Mir, Beverly Hills plastic and reconstructive surgeon Dr. Leif Rogers and board certified plastic surgeon Dr. Gregory Buford of Denver, CO, doctors reveal the unmatched benefits of using Renuvion technology in their cosmetic/aesthetic procedures.

In the video Dr. Nassif discloses that his practice uses the device four-to-five times a week in cosmetic procedures. Dr. Mir states that she gets impressive tissue contraction in areas she previously was only able to achieve through surgery, while Dr. Rogers testifies that he has tried every device on the market, and now only uses Renuvion for his procedures because it’s far superior to those other devices. Finally, Dr. Buford declares he’d stake his reputation on the safety and effectiveness of Renuvion.

Watch the video here:
Renuvion Review | Top Plastic Surgeons Talk Cutting-Edge Technology – YouTube

 

Renuvion is the only product that is FDA-cleared to improve the appearance of lax (loose) skin on the neck and submental region (chin). It was also recently cleared for specific dermatological procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II or III. These clearances highlight the safety and efficacy of the Renuvion technology.

To date, hundreds of physicians across the U.S. use Renuvion in their practices. For a list, by state, of physicians using the device visit: https://renuvionfinder.com.

For additional information visit Renuvion.com.

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision while minimizing unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, any statements regarding the potential impact of the COVID-19 pandemic and the actions by governments, businesses and individuals in response to the situation; projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration, supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the U.S. Food and Drug Administration and other governmental and regulatory bodies, both domestically and internationally; the impact of the recent FDA Safety Communication on our business and operations; factors relating to the effects of the COVID-19 pandemic; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Media Contact:

Jane Sparango
Coterie Media on behalf of Apyx Medical Corporation
jane@coteriemedia.com
310-339-1214

Investor Relations Contact:

ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/botched-tv-star-dr-paul-nassif-among-top-us-plastic-surgeons-using-renuvion-helium-plasma-technology-in-cosmetic-procedures-301622598.html

SOURCE Renuvion

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

CNN to bring its Global Perspectives events series to Bangkok

Published

on

By

Conversations to be led by CNN journalists including Dr. Sanjay Gupta, Richard Quest and Kristie Lu Stout

HONG KONG, April 21, 2026 /PRNewswire/ — CNN will hold the inaugural Asia chapter of its Global Perspectives events franchise in Bangkok, Thailand, on 14 October 2026, reinforcing the network’s commitment to convene global leaders and fostering dialogue on the critical issues shaping international business, policy and economic development.

CNN will bring together dignitaries, visionaries, political and business leaders for Global Perspectives: In Bangkok, to explore big ideas, bold leadership and the dynamic economies at the forefront of global transformation. On-stage conversations will be led by CNN’s esteemed anchors and correspondents, including Dr. Sanjay Gupta, Richard Quest, Kristie Lu Stout, Will Ripley and Hanako Montgomery, with editorial content and news-making interviews from the event featured across CNN platforms.

Expanding the Global Perspectives series with this Bangkok edition underscores CNN’s long-standing engagement in Asia. As a historic economic and cultural crossroads, Bangkok sits at the intersection of global economic dynamism, regional influence and vibrant cultural energy. The event will take place as global leaders, investors and policymakers gather in the city for the International Monetary Fund and World Bank Group Annual Meetings, creating an exclusive platform for CNN to examine a world in transition and the forces reshaping power and influence.

Ellana Lee, Group SVP, GM APAC, & Global Head of Productions at CNN, said: “Global Perspectives: In Bangkok will reflect CNN’s deep commitment to Asia and will aim to foster conversations that matter most on the global stage. At a time of rapid transformation, this event will bring together influential voices to examine the ideas, opportunities and challenges shaping the region and the world.” 

James Hunt, SVP, Head of Client Solutions & Business Lead, Global Perspectives, CNN International Commercial said: “Global Perspectives provides a unique platform for leaders and partners to engage in meaningful dialogue and connect with the forces driving global change. Hosting the event in Bangkok creates new opportunities for brand partners and sponsors to be associated with important conversations about collaboration, insight and impact at the heart of one of the world’s most dynamic regions.”

Expanding its events franchise by holding Global Perspectives: In Bangkok builds on CNN’s long-standing presence in Asia which includes a network of bureaus and correspondents across Hong Kong, Beijing, Bangkok, Taiwan, Seoul, Tokyo, New Delhi and Islamabad.

Global Perspectives is an invitation-only gathering for international decision-makers and influential leaders from across industries, including technology, finance, investment, trade, geopolitics, healthcare, media, entertainment and more. The event will be attended by heads of state, regional and global leaders, and participants can expect to form meaningful connections that will last well beyond the event itself. Global Perspectives will be hosted at The Ritz-Carlton, Bangkok. 

Further details on speakers and programming will be announced in due course. People interested in attending Global Perspectives: In Bangkok can register their interest at: https://cnnicevents.cnn.com/gpbangkok/prl

About CNN Worldwide

CNN Worldwide is the most honored brand in cable news, reaching more individuals through television, streaming and online than any other cable news organization in the United States. Globally, people across the world can watch CNN International, which is widely distributed in over 200 countries and territories. CNN Digital is the #1 online news destination, with more unique visitors than any other news source. HBO Max, Warner Bros. Discovery’s streaming platform, features CNN Max, a 24/7 streaming news offering available to subscribers alongside expanded access to News content and CNN Originals. CNN’s award-winning portfolio includes non-scripted programming from CNN Original Series and CNN Films for broadcast, streaming and distribution across multiple platforms. CNN programming can be found on CNN, CNN International and CNN en Español channels, via CNN Max and the CNN Originals hub on discovery+ and via pay TV subscription on CNN.com, CNN apps and cable operator platforms. Additionally, CNN Newsource is the world’s most extensively utilized news service partnering with over 1,000 local and international news organizations around the world. CNN is a division of Warner Bros. Discovery.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cnn-to-bring-its-global-perspectives-events-series-to-bangkok-302748000.html

SOURCE CNN International

Continue Reading

Technology

Quality Executive Partners, Inc.® Announces Exclusive Partnership with Vi’eNnI® Training and Consulting LLP to Accelerate Workforce Development in India’s Huge Pharmaceutical Sector with Virtuosi®

Published

on

By

ATLANTA and BENGALURU, India, April 21, 2026 /PRNewswire/ — Quality Executive Partners, Inc.® (QxP), a global leader in pharmaceutical quality, workforce development, regulatory compliance, and manufacturing consulting, today announced an exclusive strategic partnership with Vi’eNnI® Training and Consulting LLP to introduce and scale Virtuosi® across the Indian biopharmaceutical market.

Virtuosi helps biopharmaceutical manufacturers to solve one of their most critical operational challenges—the readiness of the workforce to perform in high-risk, high-complexity GMP environments—by building and sustaining operational capability across the employee lifecycle.

Under this agreement, Vienni will be QxP’s exclusive partner for Virtuosi in India, leading market engagement, client identification, and commercial activities.

Vi’eNnI® TRAINING & CONSULTING LLP: Enabling Scalable Training Excellence Across India

Vi’eNnI® is a recognized leader in pharmaceutical training and capability development in India, with a strong track record in GMP education, regulatory compliance, and industry engagement. Vi’eNnI® through its association with Eduoriens Skill Development LLP and professional bodies such as Parenteral Drug Association (PDA) India, Vienni operates at the center of India’s pharmaceutical training and compliance ecosystem.

With this established network, operational credibility, and relationships across India’s leading pharmaceutical manufacturers, Vienni is uniquely positioned to drive the adoption of Virtuosi at scale across the Indian market.

“This alliance is intended to deepen, enrich, and embed the field of training. The advantage of this collaboration is expected to make learning stick, with recall much higher when a participant leaves the learning zone,” said Vishal Sharma, Co-Founder Director, Vi’eNnI® TRAINING & CONSULTING LLP

“This marks the beginning of driving innovation and shaping outcomes that matter. Together, we forge a partnership that speaks the language of impact, influence, and enduring progress for teaching-learning & implementation,” said Ivy Louis, Founder Director, Vi’eNnI® TRAINING & CONSULTING LLP

“Vi’eNnI®’s mission is to empower doers to excel in their craft. This association with QxP for Virtuosi marks a pivotal step in advancing workforce capability and highlighting the strategic value of immersive training in India. We are proud to continue driving this mission forward.”

“We are honored to partner with Vi’eNnI® , a highly respected organization with deep roots in the Indian pharmaceutical industry,” said Crystal Mersh, Chief Executive Officer of Quality Executive Partners, Inc. “Together, we are enabling broader access to Virtuosi in a way that allows clients to build and sustain the knowledge, skills, and behaviors required to perform under real operating conditions. This embeds compliance and capability into daily execution in order to deliver high quality medicines to patients around the world.”

Virtuosi by QxP: Advancing Workforce Capability in India’s Globally Critical Pharmaceutical Hubs

India is one of the most critical pharmaceutical manufacturing markets globally and is poised for significant growth in the coming years, particularly across biologics, biosimilars, and advanced therapies. As manufacturers expand into more complex product categories and face increasing scrutiny from global regulatory agencies—including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) —the ability to rapidly build, standardize, and sustain a high-performing, inspection-ready workforce has become a strategic priority.

cGMP experts at QxP created Virtuosi to address this exact challenge. Virtuosi is an immersive workforce readiness program accredited by the International Accreditors for Continuing Education and Training (IACET), aligning with globally recognized standards for continuing education and distinguishing it as the only virtual reality–based training program to achieve such accreditation.

Combining virtual reality interactive experiences with digital course content, Virtuosi enables professionals to practice critical manufacturing and quality processes—such as aseptic operations, microbiology, and advanced therapies—in realistic, risk-free environments. The platform includes over 100 hours of education, 56 technical courses, and 20 immersive VR experiences, and is available in seven languages—English, French, German, Italian, Mandarin, Spanish, and Swedish—to support global workforce standardization. Virtuosi helps organizations reduce human error, accelerate time to competency, and improve compliance and operational performance across global pharmaceutical operations.

By shifting training from passive instruction to experiential learning, Virtuosi helps reduce time to competency and human error, improve inspection readiness, and drive measurable quality outcomes which translates directly to revenue protection and growth. This partnership strengthens not only the competitiveness of individual organizations, but also the long-term resilience, regulatory standing, and global leadership of India’s pharmaceutical sector.

About Quality Executive Partners, Inc.® (QxP)

Quality Executive Partners, Inc. (QxP) is a premium CGMP consulting firm focused on solving complex operational and regulatory challenges in pharmaceutical manufacturing. QxP services pharmaceutical manufactures and CDMOs globally across all major modalities – OTC, oral solid dosage, sterile, biologics, ATMPs, clinical-stage manufacturing, and combination products. We support clients throughout the product lifecycle, including clinical operations, commercial readiness, regulatory strategy, quality transformations, and remediation. Through our ‘Teach and Do®’ model, QxP embeds senior GMP experts / former regulators into day-to-day operations to execute alongside client teams and build internal capability. This model ensures solutions are effective in practice, sustainable, and directly reduce operational risk. .

About Vi’eNnI®

Vi’eNnI® Training and Consulting LLP is a pharmaceutical training and consulting organization based in Bengaluru, India, focused on advancing workforce capability, regulatory compliance, and operational excellence across the life sciences sector, for the past 16 years. The company delivers targeted training and consulting services across GMP, quality systems, aseptic processing, microbiology, and inspection readiness, competency and culture building initiatives, helping organizations strengthen performance, consolidate efficiency and achieve sustainable compliance. Known for its practical, implementation-focused approach, Vi’eNnI® enables pharmaceutical and biotechnology companies to translate training into measurable improvements on the shop floor, supporting continuous improvement and long-term capability development across India’s pharmaceutical industry with a variety of options and tools.

Media Contact (Global)
Robin Mersh
SVP, Virtuosi Sales
Quality Executive Partners, Inc.
Email: RobinMersh@QualityExecutivePartners.com
Phone: (+1) 678-496-7503

Media Contact (India)
Ivy Louis
Founder-Director
Vi’eNnI® Training and Consulting LLP
Email: Ivy_louis@vienni.com
Phone: +91 9986821045
WhatsApp: +91 9986821045

Vi’eNnI® & Virtuosi® are registered trademarks for VIENNI & Quality Executive Partners, Inc., respectively.

Logo – https://mma.prnewswire.com/media/2790799/5926395/Virtuosi_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/quality-executive-partners-inc-announces-exclusive-partnership-with-vienni-training-and-consulting-llp-to-accelerate-workforce-development-in-indias-huge-pharmaceutical-sector-with-virtuosi-302748013.html

Continue Reading

Technology

Tuniu Corporation Files Its Annual Report on Form 20-F

Published

on

By

NANJING, China, April 20, 2026 /PRNewswire/ — Tuniu Corporation (NASDAQ:TOUR) (“Tuniu” or the “Company”), a leading online leisure travel company in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 20, 2026, U.S. Eastern Time. The annual report can be accessed on the Company’s investor relations website at http://ir.tuniu.com or the SEC’s website at www.sec.gov. The Company will provide a copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Investor Relations Department at 12th floor, building 6-A, Juhuiyuan, No.108 Xuanwudadao, Xuanwu District, Nanjing, Jiangsu Province 210023, The People’s Republic of China.

About Tuniu Corporation

Tuniu (Nasdaq: TOUR) is a leading online leisure travel company in China that offers integrated travel service with a large selection of packaged tours, including organized and self-guided tours, as well as travel-related services for leisure travelers through its website tuniu.com and mobile platform. Tuniu provides one-stop leisure travel solutions and a compelling customer experience through its online platform and offline service network, including a dedicated team of professional customer service representatives, 24/7 call centers, extensive networks of offline retail stores and self-operated local tour operators. For more information, please visit http://ir.tuniu.com.

View original content:https://www.prnewswire.com/news-releases/tuniu-corporation-files-its-annual-report-on-form-20-f-302747995.html

SOURCE Tuniu Corporation

Continue Reading

Trending